Related Experiment Video

Updated: Jun 27, 2026

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

The role of KLF6 and its splice variants in cancer therapy

Analisa DiFeo1, John A Martignetti, Goutham Narla

  • 1Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, NY 10029, USA.

Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
|December 23, 2008
PubMed

Insights

The Krüppel-like factor 6 (KLF6) gene

Area of Science:

  • Molecular Biology
  • Cancer Genetics
  • Gene Regulation

Background:

  • The Krüppel-like zinc finger transcription factor (KLF6) gene regulates cancer development.
  • Alternative splicing produces KLF6 isoforms, including tumor-suppressive full-length KLF6 and oncogenic KLF6 splice variant 1 (KLF6-SV1).
  • KLF6 is inactivated in cancer, while KLF6-SV1 is overexpressed and linked to poor prognosis.

Purpose of the Study:

  • To review the dual role of KLF6 isoforms in cancer.
  • To highlight KLF6-SV1 as an oncogenic driver and potential therapeutic target.

Main Methods:

  • Review of existing literature on KLF6 gene splicing, function, and cancer association.
  • Analysis of KLF6 and KLF6-SV1 expression patterns in human cancers.
  • Examination of KLF6-SV1's oncogenic mechanisms and therapeutic potential.

Main Results:

  • Full-length KLF6 acts as a tumor suppressor through various pathways.
  • KLF6-SV1 antagonizes KLF6, promotes tumor growth, and is associated with poor outcomes in prostate, lung, and ovarian cancers.
  • Targeting KLF6-SV1 induces apoptosis, enhances chemotherapy, and reduces tumors in vivo.

Conclusions:

  • The KLF6 gene family exhibits complex roles in cancer, with KLF6 acting as a tumor suppressor and KLF6-SV1 as an oncogene.
  • KLF6-SV1 represents a promising therapeutic target for various cancers.
  • Further research into KLF6-based therapies could offer new treatment strategies for localized and metastatic cancers.

More Related Videos

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells10:06

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Published on: April 26, 2017

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Related Concept Videos

RNA Splicing01:32

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...